Shots:

• DarwinHealth will receive an upfront and eligible to receive as a commercial milestone- as part of the NCTI collaboration
• The focus of the collaboration is to identify NCTs across tumor subtypes for different cancer types by using quantitative systems biology-based algorithms- databases- and technologies and leads to the development of drugs with multi-subtype indications
• Following the NCTs discovery- BMS gets the proprietary information from DarwinHealth in its drug databases- including specific tumor analyses from MRs or MRUMs of distinct tumor subtypes

  Ref: PRNewswire | Image: BMS